Expansion of clinical and variant spectrum of EEF2-related neurodevelopmental disorder: Report of two additional cases

Am J Med Genet A. 2023 Oct;191(10):2602-2609. doi: 10.1002/ajmg.a.63230. Epub 2023 May 9.

Abstract

Eukaryotic translation elongation factor 2 (eEF2), encoded by the gene EEF2, is an essential factor involved in the elongation phase of protein translation. A specific heterozygous missense variant (p.P596H) in EEF2 was originally identified in association with autosomal dominant adult-onset spinocerebellar ataxia-26 (SCA26). More recently, additional heterozygous missense variants in this gene have been described to cause a novel, childhood-onset neurodevelopmental disorder with benign external hydrocephalus. Herein, we report two unrelated individuals with a similar gene-disease correlation to support this latter observation. Patient 1 is a 7-year-old male with a previously reported, de novo missense variant (p.V28M) who has motor and speech delay, autism spectrum disorder, failure to thrive with relative macrocephaly, unilateral microphthalmia with coloboma and eczema. Patient 2 is a 4-year-old female with a novel de novo nonsense variant (p.Q145X) with motor and speech delay, hypotonia, macrocephaly with benign ventricular enlargement, and keratosis pilaris. These additional cases help to further expand the genotypic and phenotypic spectrum of this newly described EEF2-related neurodevelopmental syndrome.

Keywords: EEF2; hydrocephalus; macrocephaly; neurodevelopmental delay; ventriculomegaly.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Autism Spectrum Disorder* / genetics
  • Child
  • Child, Preschool
  • Female
  • Genotype
  • Humans
  • Intellectual Disability* / genetics
  • Language Development Disorders* / genetics
  • Male
  • Neurodevelopmental Disorders* / genetics
  • Peptide Elongation Factor 2 / genetics
  • Phenotype

Substances

  • Peptide Elongation Factor 2